Tramadol - TheraQuest Biosciences

Drug Profile

Tramadol - TheraQuest Biosciences

Alternative Names: Sustained release tramadol; TQ-1017

Latest Information Update: 28 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraQuest Biosciences LLC
  • Developer TheraQuest Biosciences
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 08 Mar 2016 Biomarkers information updated
  • 24 Jun 2010 Discontinued - Phase-I for Neuropathic pain in USA (PO)
  • 18 Apr 2006 Extended release tramadol has received fast track status for painful HIV-associated neuropathy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top